These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 28039805)
1. Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α. Berlec A; Perše M; Ravnikar M; Lunder M; Erman A; Cerar A; Štrukelj B Int Immunopharmacol; 2017 Feb; 43():219-226. PubMed ID: 28039805 [TBL] [Abstract][Full Text] [Related]
2. Anti-tumor necrosis factor α therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis. Petito V; Graziani C; Lopetuso LR; Fossati M; Battaglia A; Arena V; Scannone D; Quaranta G; Quagliariello A; Del Chierico F; Putignani L; Masucci L; Sanguinetti M; Sgambato A; Gasbarrini A; Scaldaferri F World J Gastroenterol; 2019 Mar; 25(12):1465-1477. PubMed ID: 30948910 [TBL] [Abstract][Full Text] [Related]
3. Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. Nishitani Y; Tanoue T; Yamada K; Ishida T; Yoshida M; Azuma T; Mizuno M Int Immunopharmacol; 2009 Nov; 9(12):1444-51. PubMed ID: 19733697 [TBL] [Abstract][Full Text] [Related]
4. Mucosal delivery of Lactococcus lactis carrying an anti-TNF scFv expression vector ameliorates experimental colitis in mice. Chiabai MJ; Almeida JF; de Azevedo MGD; Fernandes SS; Pereira VB; de Castro RJA; Jerônimo MS; Sousa IG; de Souza Vianna LM; Miyoshi A; Bocca AL; Maranhão AQ; Brigido MM BMC Biotechnol; 2019 Jun; 19(1):38. PubMed ID: 31238939 [TBL] [Abstract][Full Text] [Related]
5. Preventative delivery of IL-35 by Lactococcus lactis ameliorates DSS-induced colitis in mice. Wang J; Tian M; Li W; Hao F Appl Microbiol Biotechnol; 2019 Oct; 103(19):7931-7941. PubMed ID: 31456001 [TBL] [Abstract][Full Text] [Related]
6. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918 [TBL] [Abstract][Full Text] [Related]
7. Recombinant Lactococcus lactis expressing porcine insulin-like growth factor I ameliorates DSS-induced colitis in mice. Liu S; Li Y; Deng B; Xu Z BMC Biotechnol; 2016 Mar; 16():25. PubMed ID: 26932768 [TBL] [Abstract][Full Text] [Related]
8. Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice. Shigemori S; Watanabe T; Kudoh K; Ihara M; Nigar S; Yamamoto Y; Suda Y; Sato T; Kitazawa H; Shimosato T Microb Cell Fact; 2015 Nov; 14():189. PubMed ID: 26608030 [TBL] [Abstract][Full Text] [Related]
9. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Vandenbroucke K; de Haard H; Beirnaert E; Dreier T; Lauwereys M; Huyck L; Van Huysse J; Demetter P; Steidler L; Remaut E; Cuvelier C; Rottiers P Mucosal Immunol; 2010 Jan; 3(1):49-56. PubMed ID: 19794409 [TBL] [Abstract][Full Text] [Related]
10. Oral Delivery of Mouse β-Defensin 14 (mBD14)-Producing Tian H; Li J; Chen X; Ren Z; Pan X; Huang W; Bhatia M; Pan LL; Sun J J Agric Food Chem; 2023 Apr; 71(13):5185-5194. PubMed ID: 36943701 [TBL] [Abstract][Full Text] [Related]
15. Protective effects of a novel probiotic strain, Lactococcus lactis ML2018, in colitis: in vivo and in vitro evidence. Liu M; Zhang X; Hao Y; Ding J; Shen J; Xue Z; Qi W; Li Z; Song Y; Zhang T; Wang N Food Funct; 2019 Feb; 10(2):1132-1145. PubMed ID: 30724927 [TBL] [Abstract][Full Text] [Related]
16. Unexpected effect of probiotics by Lactococcus lactis subsp. lactis against colitis induced by dextran sulfate sodium in mice. Komaki S; Haque A; Miyazaki H; Matsumoto T; Nakamura S J Infect Chemother; 2020 Jun; 26(6):549-553. PubMed ID: 32122783 [TBL] [Abstract][Full Text] [Related]
17. Le Carbone, a charcoal supplement, modulates DSS-induced acute colitis in mice through activation of AMPKα and downregulation of STAT3 and caspase 3 dependent apoptotic pathways. Afrin MR; Arumugam S; Rahman MA; Karuppagounder V; Sreedhar R; Harima M; Suzuki H; Nakamura T; Miyashita S; Suzuki K; Ueno K; Watanabe K Int Immunopharmacol; 2017 Feb; 43():70-78. PubMed ID: 27978459 [TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory properties of fermented soy milk with Lactococcus lactis subsp. lactis S-SU2 in murine macrophage RAW264.7 cells and DSS-induced IBD model mice. Kawahara M; Nemoto M; Nakata T; Kondo S; Takahashi H; Kimura B; Kuda T Int Immunopharmacol; 2015 Jun; 26(2):295-303. PubMed ID: 25887264 [TBL] [Abstract][Full Text] [Related]
19. Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis. Zurita-Turk M; Del Carmen S; Santos AC; Pereira VB; Cara DC; Leclercq SY; de LeBlanc Ad; Azevedo V; Chatel JM; LeBlanc JG; Miyoshi A BMC Biotechnol; 2014 Aug; 14():73. PubMed ID: 25106058 [TBL] [Abstract][Full Text] [Related]
20. Infliximab does not increase colonic cancer risk associated to murine chronic colitis. Lopetuso LR; Petito V; Zinicola T; Graziani C; Gerardi V; Arena V; Caristo ME; Poscia A; Cammarota G; Papa A; Cufino V; Sgambato A; Gasbarrini A; Scaldaferri F World J Gastroenterol; 2016 Nov; 22(44):9727-9733. PubMed ID: 27956796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]